drugset / Trial / NCT00012350
Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma
Phase 2
Completed
44 enrolled
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have relapsed or refractory multiple myeloma.
Timeline
- Start
- 2001-01
- Primary completion
- 2003-09
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tipifarnib | Small molecule | 300 mg | Oral |